Accepted for Publication: August 22, 2014.
Published Online: October 22, 2014. doi:10.1001/jamadermatol.2014.3234.
Study concept and design: Cosulich.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Cosulich, Molenda.
Critical revision of the manuscript for important intellectual content: Mostow, Bhatia, Brodell.
Statistical analysis: Cosulich.
Administrative, technical, or material support: Molenda, Mostow, Bhatia, Brodell.
Study supervision: Bhatia.
Conflict of Interest Disclosures: Dr Brodell reports having received honoraria from presentations for Allergan, Galderma, 3M/Graceway Pharmaceuticals, GlaxoSmithKline/Stiefel, Dermik/BenzaClin Speaker Bureau, Novartis Pharmaceuticals Corporation, sanofi-aventis, Medicis Speaker’s Bureau, PharmaDerm (a division of Nycomed US Inc), and Veregen Speakers Bureau; receiving consultant fees from Galderma Laboratories, LP, Medicis, Dow Pharmaceuticals Sciences, and Promius Pharma; serving on the advisory boards of Dow Pharmaceuticals Sciences and Nycomed US Inc; and performing clinical trials for Genentech, Galderma, Abbott Laboratories, and Dow Pharmaceuticals Science. Dr Molenda reports having partial ownership rights in projects being developed by Cleveland Clinic Innovations and receiving consulting funds from Memorial Sloan Kettering Cancer Hospital. Dr Mostow reports receiving grants for clinical trials research from HealthPoint and speakers fees from HealthPoint and Ranbaxy Laboratories. No other disclosures were reported.